Related Experiment Video
Updated: Sep 23, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept
Jeffrey M Weinberg1, Ritu Saini, William D Tutrone
1Department of Dermatology, St. Luke's-Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA. jmw27@columbia.edu
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Ulcerative Colitis in IBD
Inhibitors of Viral Protein Synthesis